Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for helicobacter pylori eradication: A randomized controlled trial

Helicobacter

Volumn 20, Issue 1, 2015, Pages 71-77

  Tsay, Feng Woei ^a,b   Wu, Deng Chyang ^c   Kao, Sung Shuo ^a   Tsai, Tzung Jium ^a   Lai, Kwok Hung ^a   Cheng, Jin Shiung ^a   Chan, Hoi Hung ^a   Wang, Huay Min ^a   Tsai, Wei Lun ^a   Tseng, Hui Hwa ^a   Peng, Nan Jin ^a   Hsu, Ping I ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHENG SHIU UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Helicobacter pylori; Reverse sequential therapy; Sequential therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PANTOPRAZOLE; UREASE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAPID UREASE TEST; REVERSE SEQUENTIAL THERAPY; STANDARD SEQUENTIAL THERAPY; TREATMENT DURATION; UREA BREATH TEST; ADOLESCENT; AGED; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920931540     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12176     Document Type: Article

References (33)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
2. Hsu PI, Lai KH, Lo GH, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002;51:15-20.
3. Hsu PI, Lai KH, Hsu PN, et al. Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 2007;102:1-6.
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
5. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific conference. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
6. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
7. Hsu PI, Kao SS. Therapy of Helicobacter pylori infection: many drugs for which association? In: Manfredi M, de'Angelis GL, eds. Helicobacter Pylori: Detection Methods, Diseases and Health Implications. New York: Nova Science Publishers, 2013;347-62.
8. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
9. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol 2004;10:668-71.
10. Bigard MA, Delchier JC, Riachi G, et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998;12:383-8.
11. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007;59:783-5.
12. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17:3971-5.
13. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
14. Gatta L, Vakil N, Leandro G, Di MF, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79.
15. Graham DY, Akiko S. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-31.
16. Jafri NS, Horning CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment. Ann Intern Med 2008;148:923-31.
17. Gisbert JP, Calvet X, O'connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25.
18. Tsay FW, Tseng HH, Hsu PI, et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012;27:498-503.
19. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
20. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100:2378-92.
21. Wu DC, Hsu PI, Tseng HH, et al. Helicobacter pylori Infection: a randomized, controlled study comparing 2 rescue thterapies after failure of standard triple therapies. Medicine 2011;90:180-5.
22. Peng NJ, Lai KH, Liu RS, et al. Endoscopic 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Dig Liver Dis 2003;35:73-7.
23. Hsu PI, Wu DC, Wu JY, et al. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011;16:146-52.
24. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori Infection. Clin Gastroenterol Hepatol 2010;8:36-41.
25. Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013;73:815-24.
26. Yoon H, Lee DH, Kim N, et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013;28:1801-9.
27. Zullo A, Hassan C, Ridola L, et al. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2013;24:16-9.
28. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day conconmitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomized trial. Lancet 2011;378(9790):507-14.
29. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: sequential therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther 2012;36:534-41.
30. Kao SS, Chen WC, Hsu PI, et al. 7-Day nonbismuth-containing concomitant therapy achieves a high eradication rate for Helicobacter pylori in Taiwan. Gastroenterol Res Pract 2012;2012:463985. doi:10.1155/2012/463985.
31. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-18.
32. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton-pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45.
33. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence based medicine rather than medicine based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.